Rhythm Pharmaceuticals is evolving from a single rare disease drug company to a broader therapeutic franchise focused on MC4R treatments. Their drug IMCIVREE has gained approval for AHO and shows strong demand with over 400 patient starts, supported by a scalable commercial model targeting specialists. The company is developing daily, weekly, and oral MC4R agonists to stay ahead of competition and expand market reach. Despite current losses and a premium valuation, accelerating U.S. sales, international expansion, and pipeline progress could justify its high valuation if momentum continues.
StoneCo reported disappointing Q2 results with revenue growing only 2.5% year-over-year and earnings per share falling short of expectations. The company is increasingly relying on credit services to drive growth, but rising delinquencies raise conce...
Zoetis is experiencing its worst stock decline ever, down 70% from its peak, due to weaker U.S. veterinary clinic visits and increased competition in key animal health segments. Despite aggressive competitor promotions, Zoetis maintains strong profit...
Google plans to relocate all Pixel device manufacturing from China to Vietnam and India by 2027, aiming to reduce supply chain risks amid US-China trade tensions. This move follows Samsung's lead and supports Google's goal to increase Pixel shipments...
Bitcoin climbed back above $64,000 after a dip below $63,000, yet the broader crypto market remains mixed with XRP and BNB falling and Bitcoin dominance rising to 58.8%. Spot Bitcoin ETFs experienced significant outflows last week, signaling reduced ...
Sea Limited, Southeast Asia's largest tech company, is considered structurally undervalued with an estimated 18% upside to a $141 per share fair value. Its diversified business model includes Shopee (e-commerce), Monee (digital financial services), a...
